Q-linea (QLINEA) investor relations material

Executive summary

• Achieved over 400% year-over-year revenue growth in 2025, with a fivefold increase in consumables run-rate and strong adoption in the US, Italy, and other regions.

• Commercial pipeline expanded rapidly, with US growth expected to accelerate after FDA clearance of an expanded menu in 2026.

• Internalized consumables production and operational restructuring reduced costs and improved gross margins, with cost savings effective January 2026.

• Restructuring at year-end 2025 led to a new organization and material reduction in OpEx starting Q1 2026.

• Leadership changes and reallocation of resources to market-oriented roles supported commercial expansion.

Financial highlights

• Net sales for 2025 reached SEK 11.1 million, up from SEK 2.4 million in 2024, with Q4 2025 net sales at SEK 2.9 million.

• Operating result (EBIT) improved to SEK -176.7 million from SEK -213.6 million year-over-year.

• Cash and cash equivalents at year-end were SEK 258.1 million, following a rights issue and capital raises totaling over SEK 312 million before costs.

• Average OpEx per month in Q4 2025 was SEK 11.7–12.5 million, with a target to reduce below SEK 11.5 million in 2026.

• Restructuring costs of SEK 6 million were recognized in 2025, covering personnel reductions for 2026.

Outlook and guidance

• Breakeven targeted for 2027, with continued focus on recurring consumables revenue, cost discipline, and gross margin expansion.

• US market expected to accelerate from Q2 2026 after FDA clearance, with significant pipeline queued for conversion.

• Targeting 70–90 contracted units by end of 2026 and 150–190 by end of 2027, up from 19 at end of 2025.

• Launch of non-blood infection testing kits planned for H2 2026 to expand addressable market.

• Additional cost savings and facility consolidation planned for 2026.